Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Yi-tzen Chen"'
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Many second-line therapies are recently approved for patients with advanced hepatocellular carcinoma (HCC), in whom protein malnutrition is prevalent that would affect treatment outcomes. In this study, we aimed to investigate the role of pre-sarcope
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0b2905fc2f3e36c25ff530374a22fa2
http://europepmc.org/articles/PMC7591538
http://europepmc.org/articles/PMC7591538
Autor:
Yee Chao, Yi Tzen Chen, Chien Wei Su, Chung Pin Li, Yi Hsiang Huang, Fa-Yauh Lee, Han-Chieh Lin, Pei Chang Lee, Ming Chih Hou, Teh Ia Huo, Mei Hsuan Lee
Publikováno v:
Liver International. 38:321-330
Background and Aims Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) but is challenging after treatment failure. Appropriate criteria for enrolling patients into second-line trials are still limited. In this study, we a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::950fa702d6a5150997f7eb2cb160aab2
https://doi.org/10.1111/liv.13527
https://doi.org/10.1111/liv.13527
Publikováno v:
Journal of Hepatology. 70:e833-e834
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24bd89695d4246a654c328a32d417193
https://doi.org/10.1016/s0618-8278(19)31664-0
https://doi.org/10.1016/s0618-8278(19)31664-0
Autor:
Fa-Yauh Lee, Yi-Tzen Chen, I-Cheng Lee, Yee Chao, Teh Ia Huo, Chien Wei Su, Chung-Pin Li, Yi Hsiang Huang, Han-Chieh Lin
Publikováno v:
Medicine
Supplemental Digital Content is available in the text
Sorafenib may improve progression-free survival (PFS) and overall survival (OS) of advanced hepatocellular carcinoma (HCC). However, the survival benefit is short lived and survivals after pr
Sorafenib may improve progression-free survival (PFS) and overall survival (OS) of advanced hepatocellular carcinoma (HCC). However, the survival benefit is short lived and survivals after pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bc2fd8a1c04a05f044f1ef9ed42136d
http://europepmc.org/articles/PMC4554055
http://europepmc.org/articles/PMC4554055
Autor:
I-Cheng Lee, Yi-Tzen Chen, Yee Chao, Teh-Ia Huo, Chung-Pin Li, Chien-Wei Su, Han-Chieh Lin, Fa-Yauh Lee, Yi-Hsiang Huang
Publikováno v:
Medicine; Apr2015, Vol. 94 Issue 14, p1-10, 10p
Publikováno v:
Gut & Liver; Nov2019, Vol. 13 Issue 6(suppl. 1), p102-102, 1/3p